Nuventra Client G1 Therapeutics Receives FDA Approval for COSELA™
Nuventra is pleased to congratulate its client, G1 Therapeutics, on the approval of COSELA™ (trilaciclib). The drug is the first therapy in its class to reduce the frequency of chemotherapy-induced…
Read More
Nuventra to Present and Exhibit at ASCPT Annual Meeting
Nuventra is proud to announce its participation at this year’s ASCPT Annual Meeting. The meeting will be held virtually from March 8–12 and March 15–17, 2021. Nuventra’s CSO and ASCPT’s…
Read More
Nuventra to Speak at PBSS Symposium on Cardiac Safety for Preclinical and Clinical Development
Nuventra’s Associate Director of Clinical Pharmacology, Lauren R. L. Lohmer, Ph.D., will be presenting during the upcoming PBSS San Francisco Symposium titled, “Cardiac Safety from Preclinical to the Clinic: Industry…
Read More
Nuventra Pharma Sciences Appoints Daniel Roy, M.H.A, as President
Nuventra Pharma Sciences announced today that Daniel Roy, M.H.A., has been appointed to the role of President. Mr. Roy joined Nuventra in 2014 as Manager of Marketing and Corporate Communication.…
Read More
Nuventra to Present on QSP and PBPK at the 2020 ACCP Virtual Roundtable
Salil Pendse, M.S., who recently joined Nuventra as a Quantitative Systems Pharmacologist, will present a roundtable discussion titled, “An Overview of QSP and PBPK: Modeling Biology in Drug Development,” at this…
Read More
Nuventra Ranks on Inc. 5000 List for Seventh Consecutive Year
Inc. Magazine revealed today that Nuventra Pharma Sciences has once again ranked on the Inc. 5000 list for 2020. This marks the seventh year in a row that Nuventra has…
Read More
Former FDA Reviewer Suliman Al-Fayoumi Joins Nuventra Pharma Sciences as Senior Consultant
Nuventra Pharma Sciences is pleased to announce the addition of Suliman Al-Fayoumi, PhD, MBA, to its growing team of experienced consultants. Dr. Al-Fayoumi has more than 20 years of experience…
Read More